Branch retinal vein occlusion (BRVO) is a common retinal vascular disease of the elderly, with a typical age of onset of around 60–70 years. The occlusion is typically a thrombus, and a number of thrombolytic and fibrinolytic approaches have been attempted to reverse BRVO in the acute setting, but these interventions have failed to show robust efficacy. Choroidal neovascularization and macular edema are common secondary complications, for which argon laser, anti-VEGF agents, steroids and intravitreal steroids have all been commonly used treatment approaches.
To provide insight into the past and predictions for the future of the field, a series of metrics were applied to the last five years of the published literature. We asked
- What are the major topics for the field?
- Which publications have the greatest impact?
- How is the knowledge available online?
- Who are the most prolific authors?
PubMed, was searched for branch retinal vein occlusion with results limited to the last five years, in humans (for a clinical focus). The data were analyzed in Microsoft Excel 2013.
